See more : E-Guardian Inc. (6050.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bionomics Limited (BNOEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bionomics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- JYP Entertainment Corporation (035900.KQ) Income Statement Analysis – Financial Results
- Ostin Technology Group Co., Ltd. (OST) Income Statement Analysis – Financial Results
- J&B International Inc. (4442.TWO) Income Statement Analysis – Financial Results
- Sau San Tong Holdings Limited (8200.HK) Income Statement Analysis – Financial Results
- National Aerospace Fasteners Corporation (3004.TW) Income Statement Analysis – Financial Results
Bionomics Limited (BNOEF)
About Bionomics Limited
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 20.00K | 260.00K | 0.00 | 50.00K | 3.82M | 8.79M | 20.79M | 14.33M |
| Cost of Revenue | 434.45K | 13.06M | 11.05M | 4.32M | 4.02M | 8.52M | 18.69M | 18.62M | 18.45M |
| Gross Profit | -434.45K | -12.63M | -6.87M | -3.62M | -1.96M | -3.35M | -9.89M | 2.17M | -4.13M |
| Gross Profit Ratio | 0.00% | -2,919.26% | -164.21% | -520.89% | -94.76% | -64.71% | -112.49% | 10.44% | -28.81% |
| Research & Development | 9.42B | 19.61M | 16.00M | 5.76M | 5.83M | 8.98M | 18.69M | 18.62M | 18.45M |
| General & Administrative | 8.47B | 5.75M | 5.11M | 3.28M | 2.53M | 4.68M | 6.86M | 4.40M | 5.61M |
| Selling & Marketing | 0.00 | 146.76K | 181.19K | 954.12K | 814.69K | 851.00K | 1.05M | 1.99M | 2.26M |
| SG&A | 8.47B | 8.86M | 7.66M | 5.65M | 4.85M | 9.35M | 7.91M | 6.40M | 7.87M |
| Other Expenses | 0.00 | 0.00 | 6.67K | 203.01K | 200.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.89B | 32.00M | 21.61M | 11.92M | 9.06M | 19.18M | 8.44M | 6.37M | 8.28M |
| Cost & Expenses | 17.89B | 22.09M | 19.32M | 6.29M | 5.01M | 10.99M | 27.12M | 24.99M | 26.73M |
| Interest Income | 0.00 | 480.00K | 10.00K | 10.00K | 60.00K | 280.00K | 1.10M | 589.10K | 497.43K |
| Interest Expense | 0.00 | 20.00K | 30.00K | 1.17M | 1.79M | 2.36M | 1.51M | 1.37M | 1.41M |
| Depreciation & Amortization | 434.45K | 778.25K | 804.54K | 1.27M | 1.64M | 1.22M | 1.29M | 1.31M | 1.41M |
| EBITDA | -9.84M | -20.90M | -11.51M | -4.97M | -4.19M | -7.87M | -16.57M | -2.88M | -10.55M |
| EBITDA Ratio | 0.00% | -4,130.83% | -275.36% | -1,006.21% | -202.73% | -152.27% | -188.39% | -13.88% | -73.65% |
| Operating Income | -17.89B | -31.97M | -21.34M | -11.92M | -9.01M | -15.36M | -17.80M | -4.22M | -11.99M |
| Operating Income Ratio | 0.00% | -4,282.63% | -290.62% | -1,107.29% | -250.19% | -171.73% | -202.42% | -20.32% | -83.72% |
| Total Other Income/Expenses | 17.88B | -2.99M | -3.01M | 1.04M | 4.85M | 7.94M | -1.63M | -562.01K | -911.70K |
| Income Before Tax | -10.27M | -32.05M | -21.95M | -8.88M | -6.03M | -9.91M | -19.43M | -4.79M | -12.91M |
| Income Before Tax Ratio | 0.00% | -4,934.35% | -362.51% | -957.30% | -201.41% | -143.60% | -220.90% | -23.02% | -90.09% |
| Income Tax Expense | -87.32M | -210.00K | -190.00K | -190.00K | -210.00K | -240.00K | 859.40K | 401.64K | 545.09K |
| Net Income | -15.49B | -31.85M | -21.76M | -8.70M | -7.12M | -9.67M | -18.57M | -5.19M | -12.36M |
| Net Income Ratio | 0.00% | -4,902.51% | -359.34% | -937.11% | -194.47% | -141.25% | -211.13% | -24.95% | -86.28% |
| EPS | -1.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.07 | -0.02 | -0.05 |
| EPS Diluted | -1.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.07 | -0.02 | -0.05 |
| Weighted Avg Shares Out | 9.99M | 1.47B | 1.35B | 779.88M | 544.83M | 521.26M | 267.94M | 267.42M | 254.03M |
| Weighted Avg Shares Out (Dil) | 9.99M | 1.47B | 1.35B | 779.88M | 544.83M | 521.26M | 267.94M | 267.42M | 256.28M |
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
Source: https://incomestatements.info
Category: Stock Reports